NDATOPICALCREAM
Approved
Jan 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
TRI-LUMA (fluocinolone acetonide, hydroquinone, and tretinoin) by Galderma is corticosteroid hormone receptor agonists [moa]. First approved in 2002.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRI-LUMA is a triple-combination topical cream containing fluocinolone acetonide (corticosteroid), hydroquinone (depigmenting agent), and tretinoin (retinoid) approved in 2002 for melasma and other hyperpigmentation disorders. It works through corticosteroid receptor agonism, melanin inhibition, and retinoid-mediated skin cell turnover to address pigmentation disorders.
LOE Approaching
LOE-approaching product with moderate competitive pressure (30/100) suggests smaller team focus and transition planning activities.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma
Started Jan 2008
56 enrolled
Melasma
Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma
Started Nov 2006
20 enrolled
Melasma
Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma
Started Nov 2006
340 enrolled
Melasma
Career Relevance
Positions linked to TRI-LUMA reflect a mature, LOE-approaching product with emphasis on market defense, managed care negotiations, and sales execution rather than growth or innovation initiatives. Career trajectories favor professionals with expertise in generic competition management, market access strategy, and customer relationship preservation.
Worked on TRI-LUMA at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.